All In Biotech

Drug Trial Radar · NCT02864992

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)

Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

337

Actual

Start

Sep 13, 2016

Primary completion

May 16, 2022

Study completion Aug 31, 2026

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Aug 12, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.

Conditions

  • Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification
  • Lung Adenocarcinoma Stage IIIB/IV

Interventions

  • TepotinibDrug

    Subjects will receive 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Cohort A: Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Independent Review Committee (IRC)Time frame: Time from first treatment up to data cutoff (approximately Month 66)
  2. Part 1: Cohort B: Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 as Assessed by Independent Review Committee (IRC)Time frame: Time from first treatment up to data cutoff (approximately Month 66)
  3. Part 2: Cohort C: Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 as Assessed by Independent Review Committee (IRC)Time frame: Time from first treatment up to data cutoff (approximately Month 66)

Locations

176 sites in 15 countries. Site status is shown where the registry gives one.

  • City of Hope Cancer Center

    Duarte, California

  • California Cancer Associates for Research & Excellence, Inc.

    Encinitas, California

  • St. Joseph Hospital

    Orange, California

  • Torrance Health Association

    Redondo Beach, California

  • St Joseph Heritage Healthcare

    Santa Rosa, California

  • Rocky Mountain Cancer Centers, LLP

    Denver, Colorado

  • Holy Cross Hospital Inc.

    Fort Lauderdale, Florida

  • H. Lee Moffitt Cancer Center and Research Institute, Inc

    Tampa, Florida

  • University Cancer & Blood Center, LLC

    Athens, Georgia

  • Winship Cancer Institute

    Atlanta, Georgia

  • University of Chicago Medical Center

    Chicago, Illinois

  • Ingalls Hospital

    Harvey, Illinois

  • Community Regional Cancer Care

    Indianapolis, Indiana

  • Center for Cancer and Blood Disorders

    Bethesda, Maryland

  • For Recruiting Locations in the United States, please Contact U.S. Medical Information

    Rockland, Massachusetts

  • St. Louis Cancer Care, LLP

    Bridgeton, Missouri

  • Saint Louis University Cancer Center

    St Louis, Missouri

  • Saint Louis University

    St Louis, Missouri

  • Summit Medical Group, P.A.

    Berkeley Heights, New Jersey

  • Summit Medical Group

    Berkeley Heights, New Jersey

  • Regional Cancer Care Associates East Brunswick

    East Brunswick, New Jersey

  • Somerset Hematology Oncology Associates - Somerville Location

    East Brunswick, New Jersey

  • Hackensack University Medical Center PARTNER

    Hackensack, New Jersey

  • Prospect Medical Offices, LLC

    Midland Park, New Jersey

  • The Valley Hospital

    Ridgewood, New Jersey

  • Memorial Sloan Kettering Cancer Center - Commack

    Commack, New York

  • Memorial Sloan Kettering Cancer Center, West Harrison Regional Outpatient Pavilion

    Harrison, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • UC Health Clinical Trials Office

    Cincinnati, Ohio

  • University of Cincinnati - PARENT

    Cincinnati, Ohio

  • Tennessee Oncology

    Nashville, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Texas Oncology, P.A. - Austin

    Austin, Texas

  • Texas Oncology, PA

    Beaumont, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia

  • Swedish Medical Center

    Seattle, Washington

  • Wenatchee Valley Hospital & Clinics - ATTN: Jay Johnson

    Wenatchee, Washington

  • Wenatchee Valley Medical Center Oncology

    Wenatchee, Washington

  • LKH - Universitätsklinikum der PMU Salzburg - Innere Med III/Hämatologie und Onkologie

    Salzburg, Austria

Showing 40 of 176 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.